SCH 52365 Phase II Clinical Study: A Study on the Efficacy & Safety of

Clinical Trial Summary

The primary purpose of the study is to evaluate the efficacy (overall response) and safety of temozolomide in Step 1 at the dose and regimen approved in the US and the EU countries (28 day cycles of temozolomide at 150 to 200 mg/m2 once daily for 5 consecutive days with a 23 day rest period) in patients with anaplastic astrocytoma at first relapse.

See also
Status	Clinical Trial	Phase
Terminated	`NCT02764151` - First in Patient Study for PF-06840003 in Malignant Gliomas	Phase 1
Completed	`NCT00994071` - A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	Phase 1
Terminated	`NCT01502605` - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas	Phase 1
Completed	`NCT02903784` - Neural Basis of Language Processing	N/A
Terminated	`NCT01044966` - A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma	Phase 1/Phase 2
Completed	`NCT00705198` - Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)	N/A
Completed	`NCT00165360` - Prolonged Daily Temozolomide for Low-Grade Glioma	Phase 2
Active, not recruiting	`NCT03911388` - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors	Phase 1
Terminated	`NCT00389090` - A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma	Phase 2
Completed	`NCT00154375` - Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma	Phase 3
Completed	`NCT00001148` - Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor	N/A
Completed	`NCT03722355` - Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma	Phase 3
Recruiting	`NCT03975829` - Pediatric Long-Term Follow-up and Rollover Study	Phase 4
Recruiting	`NCT05686798` - Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.	Phase 1
Active, not recruiting	`NCT03739372` - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma	N/A
Recruiting	`NCT05624736` - Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
Recruiting	`NCT05345002` - All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma	Phase 2
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed	`NCT03900689` - Social Determinants of Health in Glioblastoma Population
Completed	`NCT02747407` - Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

NCT number	NCT00783393
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 2
Start date	May 27, 2003
Completion date	June 17, 2005

SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms